• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂-1 4G/5G多态性与冠状动脉疾病风险:一项荟萃分析。

PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis.

作者信息

Liang Zhongshu, Jiang Weihong, Ouyang Mao, Yang Kan

机构信息

Department of Cardiology, The Third Xiangya Hospital of Central South University 138 Tongzipo Road, Changsha 410013, Hunan, China.

出版信息

Int J Clin Exp Med. 2015 Feb 15;8(2):2097-107. eCollection 2015.

PMID:25932140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4402787/
Abstract

Many epidemiologic studies have investigated the plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G polymorphism and this association with coronary artery disease (CAD). But definite conclusions can not be drawn. Related studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) till 10 August 2014. Pooled ORs and 95% CIs were used to assess the strength of the associations. A total of 53 studies including 20921 CAD cases and 18434 controls were included. Significantly elevated CAD risk was found in overall analysis (OR = 1.13, 95% CI: 1.05-1.21, P = 0.0009). In the subgroup analysis by races, significantly increased risk was found in Caucasians (OR = 1.11, 95% CI: 1.03-1.20, P = 0.005) and Asians (OR = 1.20, 95% CI: 1.01-1.42, P = 0.04). In the subgroup analysis by gender, significant association was found in males (OR = 1.15, 95% CI: 1.06-1.25, P = 0.0008), but was not found in females (OR = 1.05, 95% CI: 0.92-1.20, P = 0.47). In the subgroup analysis by age, young populations showed increased CAD risk (OR = 1.19, 95% CI: 1.02-1.37, P = 0.02), but old populations did not show this association (OR = 1.01, 95% CI: 0.82-1.24, P = 0.93). This meta-analysis provides the evidence that PAI-1 4G/5G polymorphism may contribute to the CAD development.

摘要

许多流行病学研究调查了纤溶酶原激活物抑制剂-1(PAI-1)基因4G/5G多态性及其与冠状动脉疾病(CAD)的关联。但尚未得出明确结论。截至2014年8月10日,从PubMed、Springer Link、Ovid、中国万方数据知识服务平台、中国知网(CNKI)和中国生物医学数据库(CBM)中检索到相关研究。采用合并OR值和95%可信区间(CI)评估关联强度。共纳入53项研究,包括20921例CAD病例和18434例对照。总体分析发现CAD风险显著升高(OR = 1.13,95%CI:1.05 - 1.21,P = 0.0009)。种族亚组分析中,白种人(OR = 1.11,95%CI:1.03 - 1.20,P = 0.005)和亚洲人(OR = 1.20,95%CI:1.01 - 1.42,P = 0.04)的风险显著增加。性别亚组分析中,男性存在显著关联(OR = 1.15,95%CI:1.06 - 1.25,P = 0.0008),而女性未发现(OR = 1.05,95%CI:0.92 - 1.20,P = 0.47)。年龄亚组分析中,年轻人群CAD风险增加(OR = 1.19,95%CI:1.02 - 1.37,P = 0.02),而老年人群未显示此关联(OR = 1.01,95%CI:0.82 - 1.24,P = 0.93)。这项荟萃分析提供了证据表明PAI-1 4G/5G多态性可能与CAD的发生有关。

相似文献

1
PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis.纤溶酶原激活物抑制剂-1 4G/5G多态性与冠状动脉疾病风险:一项荟萃分析。
Int J Clin Exp Med. 2015 Feb 15;8(2):2097-107. eCollection 2015.
2
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis.纤溶酶原激活物抑制剂-1 4G/5G多态性与冠状动脉疾病风险相关:一项荟萃分析。
Int J Clin Exp Med. 2014 Oct 15;7(10):3777-88. eCollection 2014.
3
Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population.纤溶酶原激活物抑制剂-1 4G/5G多态性与糖尿病肾病的关联:中国人群的一项荟萃分析。
Int Urol Nephrol. 2016 Sep;48(9):1483-9. doi: 10.1007/s11255-016-1333-9. Epub 2016 Jun 6.
4
Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.纤溶酶原激活物抑制剂-1 4G/5G多态性与静脉血栓栓塞风险的关联:一项荟萃分析。
Thromb Res. 2014 Dec;134(6):1241-8. doi: 10.1016/j.thromres.2014.09.035. Epub 2014 Oct 5.
5
Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.纤溶酶原激活物抑制剂-1基因多态性与中风易感性之间的关联。
Mol Neurobiol. 2017 Jan;54(1):328-341. doi: 10.1007/s12035-015-9549-8. Epub 2016 Jan 7.
6
PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.纤溶酶原激活物抑制剂-1启动子4G/5G多态性(rs1799768)与肿瘤易感性相关:荟萃分析证据
Exp Ther Med. 2012 Dec;4(6):1127-1133. doi: 10.3892/etm.2012.734. Epub 2012 Oct 2.
7
Plasminogen Activator Inhibitor-1 Polymorphisms and Risk of Coronary Artery Disease: Evidence From Meta-Analysis and Trial Sequential Analysis.纤溶酶原激活物抑制剂-1 多态性与冠心病风险:来自荟萃分析和试验序贯分析的证据。
Biochem Genet. 2022 Oct;60(5):1409-1445. doi: 10.1007/s10528-021-10143-x. Epub 2022 Jan 18.
8
Factor XIII-A Val34Leu polymorphism might beassociated with myocardial infarction risk: an updated meta-analysis.凝血因子 XIII-A Val34Leu 基因多态性可能与心肌梗死风险相关:一项更新的荟萃分析。
Int J Clin Exp Med. 2014 Dec 15;7(12):5547-52. eCollection 2014.
9
Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss.纤溶酶原激活物抑制剂-1 4G/5G多态性与复发性流产关联的Meta分析
Med Sci Monit. 2015 Apr 11;21:1051-6. doi: 10.12659/MSM.892898.
10
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review.纤溶酶原激活物抑制剂-1(PAI-1)4G/5G启动子多态性与静脉血栓栓塞风险——一项荟萃分析与系统评价
Vasa. 2020 Mar;49(2):141-146. doi: 10.1024/0301-1526/a000839. Epub 2020 Jan 10.

引用本文的文献

1
Genetic Associations of Plasminogen Activator Inhibitor-1-Related miRNA Variants with Coronary Artery Disease.纤溶酶原激活物抑制剂-1 相关 miRNA 变异与冠状动脉疾病的遗传关联。
Int J Mol Sci. 2024 Oct 27;25(21):11528. doi: 10.3390/ijms252111528.
2
The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction.纤溶酶原激活物抑制剂-1启动子中4G/5G多态性对新冠病毒疾病严重程度和内皮功能障碍的影响。
Front Immunol. 2024 Aug 30;15:1445294. doi: 10.3389/fimmu.2024.1445294. eCollection 2024.
3
Increased plasminogen activator inhibitor-1 (PAI-1) and its associations with metabolic risk in healthy young adults with early life stress.健康的青年成年人在生命早期经历压力时,纤溶酶原激活物抑制剂-1(PAI-1)增加及其与代谢风险的关系。
Psychoneuroendocrinology. 2024 Aug;166:107071. doi: 10.1016/j.psyneuen.2024.107071. Epub 2024 May 8.
4
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review.无传统可调节危险因素的患者的冠状动脉粥样硬化临床路径:JACC 现状评价。
J Am Coll Cardiol. 2023 Sep 26;82(13):1343-1359. doi: 10.1016/j.jacc.2023.06.045.
5
Systematic Review and Meta-Analysis of 4G/5G Insertion/Deletion Variant With Circulating Lipid Levels.4G/5G插入/缺失变异与循环血脂水平的系统评价和荟萃分析
Front Cardiovasc Med. 2022 Jun 23;9:859979. doi: 10.3389/fcvm.2022.859979. eCollection 2022.
6
Etiologic Puzzle of Coronary Artery Disease: How Important Is Genetic Component?冠状动脉疾病的病因之谜:遗传因素有多重要?
Life (Basel). 2022 Jun 9;12(6):865. doi: 10.3390/life12060865.
7
PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?PAI-1:阻塞性睡眠呼吸暂停中血管功能障碍的主要参与者?
Int J Mol Sci. 2022 May 15;23(10):5516. doi: 10.3390/ijms23105516.
8
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
9
The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population.纤溶酶原激活物抑制剂-1(PAI-1)基因多态性与代谢综合征对韩国人群冠状动脉疾病的协同作用。
J Pers Med. 2020 Nov 28;10(4):257. doi: 10.3390/jpm10040257.
10
Lack of Associations Between and Polymorphisms and Arterial Ischemic Stroke in Children: A Systematic Review and Meta-Analysis.与动脉缺血性脑卒中的相关性研究:系统评价与荟萃分析。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619869500. doi: 10.1177/1076029619869500.

本文引用的文献

1
Genome-wide studies of gene expression relevant to coronary artery disease.与冠状动脉疾病相关的基因表达的全基因组研究。
Curr Opin Cardiol. 2012 May;27(3):210-3. doi: 10.1097/HCO.0b013e3283522198.
2
PAI-1 4G/5G polymorphism and plasma levels association in patients with coronary artery disease.纤溶酶原激活物抑制物-1 4G/5G 多态性与冠心病患者血浆水平的相关性。
Arq Bras Cardiol. 2011 Dec;97(6):462-389. doi: 10.1590/s0066-782x2011005000110. Epub 2011 Oct 21.
3
Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction.组织型纤溶酶原激活物和纤溶酶原激活物抑制剂多态性在心肌梗死中的作用。
Mol Biol Rep. 2011 Apr;38(4):2541-8. doi: 10.1007/s11033-010-0392-8. Epub 2010 Nov 17.
4
Platelet polymorphisms: frequency distribution and association with coronary artery disease in an Indian population.血小板多态性:在印度人群中的频率分布及与冠状动脉疾病的关系。
Platelets. 2011;22(2):85-91. doi: 10.3109/09537104.2010.522275. Epub 2010 Oct 29.
5
4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries.4G/5G 多态性和载脂蛋白 E 基因多态性与冠状动脉粥样硬化性疾病的关系。
Thromb Haemost. 2010 Jun;103(6):1170-80. doi: 10.1160/TH09-10-0702. Epub 2010 Mar 29.
6
Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study.心肌梗死中纤溶酶原激活物抑制因子-1(PAI-1)4G/5G和-844G/A基因多态性与PAI-1/组织纤溶酶原激活物水平变化的关联:一项病例对照研究
Genet Test Mol Biomarkers. 2010 Feb;14(1):23-7. doi: 10.1089/gtmb.2009.0039.
7
Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.凝血酶激活的纤溶抑制因子遗传多态性作为急性冠状动脉综合征类型的标志物。
Thromb Res. 2009 Nov;124(5):614-8. doi: 10.1016/j.thromres.2009.07.004. Epub 2009 Aug 21.
8
Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients.纤溶酶原激活物抑制剂-1基因4G/5G多态性与年轻患者ST段抬高型急性心肌梗死的相关性
Rev Esp Cardiol. 2009 Apr;62(4):365-72. doi: 10.1016/s1885-5857(09)71663-9.
9
Impact of hemostatic gene single point mutations in patients with non-diabetic coronary artery disease.非糖尿病性冠心病患者止血基因单点突变的影响。
Mol Biol Rep. 2009 Nov;36(8):2235-43. doi: 10.1007/s11033-008-9439-5. Epub 2009 Jan 3.
10
Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease.纤溶酶原激活物抑制剂-1(PAI-1)和白细胞介素-6(IL-6)基因多态性与吸烟在确定它们与冠状动脉疾病相关风险中的协同作用。
Clin Biochem. 2008 May;41(7-8):467-73. doi: 10.1016/j.clinbiochem.2008.01.028. Epub 2008 Feb 15.